Category

News
In patients with newly diagnosed multiple myeloma (MM) who are ineligible for high-dose chemotherapy and transplantation, adding daratumumab to bortezomib, melphalan, and prednisone (VMP) halved the risk of disease progression or death, compared with VMP alone, according to updated results from the phase III ALCYONE trial. The findings, which were published in The Lancet, also point...
Continue Reading
Mark Wellington cherished the final years he spent with his wife after she was diagnosed with multiple myeloma. Now he wants Pharmac to make good on its promise to fund for others one of the drugs which extended her life. Mark’s wife, Jocelyn, died last month, aged 69, four years after being diagnosed with the...
Continue Reading
Myeloma New Zealand is today calling on Pharmac to make good on their proposal to widen access to blood cancer treatment lenalidomide (Revlimid) from April this year, allowing eligible patients access the subsidised drug earlier in their course of treatment. As one of several groups that marched on Parliament in 2019 presenting petitions demanding an...
Continue Reading
Media Release In a move welcomed by patient advocacy group Myeloma New Zealand, drug buying agency Pharmac has proposed to widen access to blood cancer treatment lenalidomide (Revlimid).  Myeloma is an incurable type of blood cancer that starts in the bone marrow and leads to serious complications such as kidney failure, bone pain and infections....
Continue Reading
Results from a new study at Hutchinson Cancer Research Cancer in Seattle suggests that chimeric antigen receptor (CAR) T-cell therapy can be further improved for multiple myeloma. The approach relies on a class of drugs known as gamma-secretase inhibitors (GSIs), several of which have been studied to treat Alzheimer disease but were never approved for...
Continue Reading
The Prime Minister has acknowledged Blair Vining’s “tireless advocacy” as the new independent Cancer Control Agency was formally opened on Tuesday. During Vining’s final months, as he was dying from cancer, the Southlander pushed for the Government to set up an independent cancer agency to improve cancer care for New Zealanders. In September, a matter of weeks before Vining died,...
Continue Reading
Starting Saturday, December 7, HemOnc Today will be onsite in Orlando at the ASH Annual Meeting and Exposition, bringing the latest in important, novel hematology research to our daily feed, with a special focus on multiple myeloma. HemOnc Today spoke with Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center,...
Continue Reading
A summary of events and the status of medicines applications for myeloma currently with Pharmac   Tania Crosbie Special Projects Manager, Myeloma New Zealand   Despite advertising that Pharmac would be responding to the Health Select Committee (HSC) with regards to the myeloma petition at the Wednesday October 23rd HSC meeting, no oral feedback was...
Continue Reading
The objective of the study was to assess racial disparities in the treatment and outcomes among white, African American, and Hispanic patients with multiple myeloma (MM). Patients with an MM diagnosis from the Surveillance Epidemiology and End Results (SEER)–Medicare (2007-2013) database were included. Continuous Medicare enrollment for 6 months before (baseline) and after MM diagnosis...
Continue Reading
There are issues involving Pharmac and how they fund medicines – Pharmac does not adopt international guidelines; it does not set a timeframe by which it will be decided if a medicine is efficacious and another timeframe when it will endeavour to fund a medicine if it is deemed to be efficacious; it needs to...
Continue Reading
1 2 3 20

Floor 7, 90 The Terrace
Wellington Central
New Zealand